1372
disease-modifying therapies (DMT), such as interferon beta and glatiramer acetate, offer significant benefits to patients with MS,7,14–22 they may be ineffective in treating NMO.12 Furthermore, individual case reports indicate that natalizumab and alemtuzumab may be unsuitable for the treatment of NMO.23–25 Although no controlled studies have yet been conducted on the use of first-line MS DMT in patients with NMO, there are a number of case series reporting disease exacerbation26,27 and lack of efficacy fol-lowing treatment initiation.28–30 In addition, some immu-nosuppressive therapies (e.g. azathioprine) typically used to treat NMO may have limited benefit and/or unaccepta-ble toxicity for individuals with MS.31 To avoid the delays in treatment initiation that are associated with diagnostic uncertainty, this report offers guidance on the appropriate treatment decision for patients presenting with idiopathic inflammatory demyelinating disease.
Multiple Sclerosis Journal 19(10)
Clinical and magnetic resonance imaging (MRI) features
○ Acute myelopathy and a spinal MRI showing a fully contiguous long cord lesion (≥3 spinal seg-ments), centrally located in the post-acute phase○ Simultaneous bilateral severe optic neuritis○ Acute visual failure, with chiasmal MRI lesion○ Altitudinal hemianopia
○ Intractable hiccough (lasting >2 days) or vomit-ing, with evidence of a linear medullary peri-aqueductal lesion on MRI
○ Clinically manifested systemic lupus erythema-tous (SLE) or Sjögren’s syndrome
Laboratory features
○ Positive anti-aquaporin4 (AQP4) antibody/NMO- immunoglobulin (IgG) assay measured by a validated laboratoryPatients with any of these clinical and paraclinical fea-tures are considered unlikely to benefit from first-line DMT because their presentation is more characteristic of inflam-matory demyelinating diseases other than MS. In fact, fully contiguous long spinal cord lesions (≥3 segments in length) represent one of three supportive criteria, and arguably the most distinctive feature, for a diagnosis of NMO.33 However, patients with fully contiguous long cord lesions, who are negative for anti-AQP4 antibody/NMO-IgG, have been found to respond positively to interferon beta-1b with significantly lower on-treatment than pre-treatment relapse rates.35 While fully contiguous long cord lesions are defined as those that span three or more spinal segments,33 the abso-lute lesion length can vary depending on the section of the spinal cord involved; for example, three cervical segments are shorter than three thoracic segments.
The location of a cervical lesion in the axial plane can also assist in distinguishing MS from non-MS. One study found more than 80% of cervical lesions to be localized to the lateral and posterior areas of white matter in patients during the acute and chronic stages of MS, while 50% of all chronic spinal cord lesions were centrally located in the grey matter of patients with NMO.36
Given its high frequency in patients with NMO,37 simul-taneous bilateral severe optic neuritis may also assist in differentiating MS from non-MS. With regard to the nature of the visual disturbance, a comparison of NMO and McDonald MS patients found altitudinal hemianopia to be exclusive to NMO.38 We included protracted hiccough among the constellation of clinical symptoms indicative of patients unlikely to benefit from first-line MS DMT because of its prevalence among patients with NMO (17%, 8/47) versus MS (0%, 0/130) in a study by Misu et al.39 This is supported pathologically, with lesions found in the nucleus tractus solitarius (the brain structure involved in the dia-phragmatic reflex) in a patient diagnosed post-mortem with
Methods
An expert committee composed of MS neurologists from the Asia-Pacific region reviewed existing literature and discussed anecdotal evidence derived from clinical prac-tice to develop recommendations for the early treatment of patients presenting with idiopathic inflammatory demyelinating disease. Based on whether clinical and paraclinical features pointed towards MS or NMO, we defined: (a) patients in whom first-line DMT for MS are unlikely to be effective; (b) those patients for whom first-line MS DMT may be administered and who require care-ful monitoring and (c) those patients likely to benefit from first-line MS DMT.
The first two categories refer to patients with events atypical for MS and for whom alternative disease processes remain possible. The third category describes patients with events typical of MS and in whom alternative diagnoses have been excluded. These patients, as well as those with NMO, will not be discussed in detail in this article, as treat-ment guidelines for these patient classes have recently been published.32–34
The first version of this consensus statement was pre-sented at the second Pan-Asian Committee on Treatment and Research of Multiple Sclerosis (PACTRIMS) confer-ence in Hong Kong (November 2009). Following this con-ference, the statement was revised to include information available up to February 2012. The amended version of this consensus statement is presented here.
The consensus statement
Category 1. Patients in whom first-line MS DMT are unlikely to be effective
In patients who present with any of the following features, first-line MS DMT are unlikely to be effective:
【医脉通_临床医学_医药卫生_专业资料。心电与循环 2014 年第 33 卷第 6 期 欧美肺动脉高压诊疗指南解读郭航远 郭航远 , 浙江 大学 绍兴 医院 (绍兴 市人民...
【医脉通_临床医学_医药卫生_专业资料。2015 ADA /EASD 2 型糖尿病管理指南概要(编译) 2015.1.28 近年随着降糖药物种类增多,临床医生在选择与应用降糖药物方面存...
【医脉通_基础医学_医药卫生_专业资料。网络出版时间:2014-12-04 16:57 网络...骨髓间充质干细胞移植对胆道缺血性狭窄的防治作用研究[J].中国普 通外科杂志,...
【医脉通_临床医学_医药卫生_专业资料。临床指南中国原发性肺癌诊疗规范( 2015 年版)一、概述(一)前言 原发性肺癌 (以下简称肺癌)是我国最常见的恶性肿瘤之一。...
【医脉通_临床医学_医药卫生_专业资料。中华妇幼临床医学杂志 ( 电子版 )201 4年1 2 月第 10 卷第 6期 ·733· · 标准 · 方案 · 指南 · 儿童过敏...
【医脉通_临床医学_医药卫生_专业资料。主堡』L型盘查!!!篁!旦筮!!鲞筮!翅垦!i!』里型堕!,』!!!盟!Q!!:∑!!:!!:塑!:! .标准.方案.指南. 儿童...
医脉通临床指南 http://guide.medlive.cn/ 胸痛规范化评估与诊断中国专家共识胸痛是一种常见的临床症状,病因繁杂,涉及多个器官和系统,病情程度轻重不一,规范 化...
【医脉通_临床医学_医药卫生_专业资料。D 6 专题 2014 年 12 月 4 日 星期四 计, 2013 年报告的丙肝患者超 20 万, 较 2005 年增加约 3 倍。而大部分...
【医脉通_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 【医脉通_临床医学_医药卫生_专业资料。中国实用外科杂志 2015 年 1 月第 35 卷...
【医脉通_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 【医脉通_临床医学_医药卫生_专业资料。< W $3 G/ 1T " FG@ G7 , < 7 "...
热门文档